Clinical Trial: Immune Modulation Therapy for Pompe Disease
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Immune Modulation Therapy for ERT-naïve or ERT-treated Pompe Disease Patients
Brief Summary: The purpose of this study is to assess anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers after treatment with immune modulation therapy in patients of Pompe disease.
Detailed Summary:
Sponsor: National Taiwan University Hospital
Current Primary Outcome: anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers decrease [ Time Frame: 6 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: National Taiwan University Hospital
Dates:
Date Received: August 10, 2015
Date Started: August 2015
Date Completion: July 2020
Last Updated: April 13, 2016
Last Verified: April 2016